MetaCap

Avalo Therapeutics Inc. (AVTX)

NASDAQ: AVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.76+0.01 (+0.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AVTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$390.88M
EPS (TTM)
-$2.26
52-week range
6.53 – 24.27
Day range
6.61 – 7.03
Volume / Avg
1.18M / 1.80M
Beta
—

52-week range

$6.53$24.27

AVTX stock today

Avalo Therapeutics (AVTX) closed at $6.76 on Nov 20, up 0.15% (+$0.01), versus the S&P 500's 3.70% decline. Shares are 72.1% below their 52-week high of $24.27, set on May 7, 2026 and 3.5% above the 52-week low of $6.53, near the bottom of the past year's range. AVTX is down 62.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.1%.

Avalo Therapeutics has posted a net loss over the last twelve months (EPS of -$2.26), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Avalo Therapeutics

Company profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Garry A. Neil M.D.
Headquarters
Wayne, PA
Employees
33
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Avalo Therapeutics generated $59,000 in revenue, down 86.6% from fiscal 2024, its first annual decline since 2024. Avalo Therapeutics reported a net loss of $78.3 million, compared with a loss of $35.1 million a year earlier. Operating margin was -123601.7%.

Avalo Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$59.00K$441.00K$1.92M$18.05M$5.40M
Growth-86.62%-77.08%-89.34%+234.40%-19.42%
Net income$-78.26M$-35.13M$-31.54M$-41.66M$-84.38M
EPS (diluted)$-5.84$-20.91$-113.58$-1,063.00—

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$34.80+414.79%

  • Strong buy 2
  • Buy 10
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $60.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.34 vs $-0.63
Surprise
+46.03%

AVTX news

All AVTX news

Avalo Therapeutics peers

Health Care sector
AVTX peer companies
CompanyPrice% ChgMarket capCompare
OCSOculis Holding AG7.06-5.11%$393.35Mvs AVTX
IRDOpus Genetics Inc.3.99-2.21%$385.65Mvs AVTX
PHATPhathom Pharmaceuticals Inc.4.66-8.27%$378.82Mvs AVTX
OVIDOvid Therapeutics Inc.2.20-5.98%$415.21Mvs AVTX
PBYIPuma Biotechnology Inc7.05-0.98%$364.47Mvs AVTX
CRMDCorMedix Inc.5.27+3.74%$419.16Mvs AVTX
ASPEAspen Neuroscience Inc.12.42+0.24%$361.16Mvs AVTX
PRTAProthena Corporation plc8.22-2.14%$422.10Mvs AVTX

Indexes, lists and sector

Avalo Therapeutics stock FAQ

What is Avalo Therapeutics's stock price today?

AVTX last traded at $6.76 as of Nov 20, 4:00 PM EST, up 0.15% on the day. Prices are delayed at least 15 minutes.

Does Avalo Therapeutics pay a dividend?

No. Avalo Therapeutics does not currently pay a regular cash dividend.

Who is Avalo Therapeutics's CEO?

Dr. Garry A. Neil M.D. is the chief executive officer of Avalo Therapeutics Inc., which has about 33 employees.

Has AVTX ever split its stock?

Yes. The most recent AVTX stock split was a 1-for-240 split on Dec 29, 2023, one of 2 splits on record.

What is the AVTX 52-week high?

The 52-week high for AVTX is $24.27 and the 52-week low is $6.53. The stock is currently 72.1% below its high.

Compare AVTX